Glucocorticoids and vascular reactivity

Current Vascular Pharmacology

Volumn 2, Issue 1, 2004, Pages 1-12

  Yang, Shumei ^a   Zhang, Lubo ^b  

^a CALIFORNIA STATE UNIVERSITY   (United States)

^b LOMA LINDA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

11 hydroxysteroid dehydrogenase; Endothelium; Glucocorticoids; Nitric oxide; Pharmacomechanical coupling; Prostacyclin; Vascular smooth muscle

Indexed keywords

11BETA HYDROXYSTEROID DEHYDROGENASE; ACETYLCHOLINE; CALCIMYCIN; CARBENOXOLONE; CATECHOLAMINE RECEPTOR; CAVEOLIN; CORTICOSTEROID DERIVATIVE; CORTICOSTEROID RECEPTOR; CORTISONE; DEXAMETHASONE; ENDOTHELIUM DERIVED HYPERPOLARIZING FACTOR; GLUCOCORTICOID; GLUCOCORTICOID RECEPTOR; HYDROCORTISONE; ISOENZYME; MESSENGER RNA; MIFEPRISTONE; MINERALOCORTICOID RECEPTOR; N ACETYL S NITROSOPENICILLAMINE; N(G) METHYLARGININE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE INHIBITOR; NITRITE; NITROPRUSSIDE SODIUM; NORADRENALIN; PROSTACYCLIN; PROSTAGLANDIN; UNINDEXED DRUG; VASODILATOR AGENT;

ARTERY CONSTRICTION; BLOOD VESSEL REACTIVITY; CATALYSIS; CLINICAL TRIAL; DRUG MECHANISM; DRUG RECEPTOR BINDING; ENDOTHELIUM CELL; ENZYME ACTIVITY; ENZYME INHIBITION; HORMONE SENSITIVITY; HUMAN; HYPERTENSION; MUSCLE TONE; NONHUMAN; PATHOPHYSIOLOGY; PROSTAGLANDIN SYNTHESIS; PROTEIN EXPRESSION; REVIEW; SMOOTH MUSCLE FIBER; VASCULAR ENDOTHELIUM; VASCULAR RESISTANCE; VASCULAR SMOOTH MUSCLE;

11-BETA-HYDROXYSTEROID DEHYDROGENASES; ANIMALS; BLOOD PRESSURE; ENDOTHELIUM, VASCULAR; EPOPROSTENOL; GLUCOCORTICOIDS; HUMANS; HYDROCORTISONE; ISOENZYMES; MUSCLE, SMOOTH, VASCULAR; NITRIC OXIDE SYNTHASE; RECEPTORS, GLUCOCORTICOID; VASOCONSTRICTION;

EID: 3042781466     PISSN: 15701611     EISSN: None     Source Type: Journal    
DOI: 10.2174/1570161043476483     Document Type: Review

References (169)

1. Brem AS, Bina RB, Hill N, Alia C, Morris DJ. Effects of licorice derivatives smooth muscle function, Life Sci 1997; 60: 207-14.
2. Darlington DN, Kaship K, Keil LC, Dallman MF. Vascular responsiveness in adrenalectomized rats with corticosterone replacement. Am J Physiol 1989: 256: H1274-81.
3. Keller-Wood M. Vasopressin response to hyperosmolality and hypotension during ovine pregnancy. Am J Physiol 1994: 266: R188-93.
4. Kornel L. The role of vascular steroid receptors in the control of vascular contractility and peripheral vascular resistance. J Steroid Biochem Mol Biol 1993; 45: 195-203.
5. Ullian ME. The role of corticosteriods in the regulation of vascular tone. Cardiovasc Res 1999; 41: 55-64.
6. van Uum SH, Hermus AR, Smits P, Thien T, Lenders JW. The role of 11 beta-hydroxysteroid dehydrogenase in the pathogenesis of hypertension. Cardiovasc Res 1998; 38: 16-24.
7. Walker BR, Yau JL, Brett LP, Seekl JR, Monder C, Williams BC, et al. 11 beta-hydroxysteroid dehydrogenase in vascular smooth muscle and heart: implications for cardiovascular responses to glucocorticoids. Endocrinology 1991; 129: 3305-12.
8. Yagil Y, Krakoff LR. The differential effect of aldosterone and dexamethasone on pressor responses in adrenalectomized rats. Hypertension 1988; 11: 174-8.
9. Kelly JJ, Mangos G, Williamson PM, Whitworth JA. Cortisol and hypertension. Clin Exp Pharmacol Physiol 1998; 25: S51-6.
10. Whitworth JA, Schyvens CG, Zhang Y, Mangos GJ, Kelly JJ. Glucocorticoid-induced hypertension: from mouse to man. Clin Exp Pharmacol Physiol 2001; 28: 993-6.
11. Britten MB, Zeiher AM, Schächinger V. Clinical importance of coronary endothelial vasodilator dysfunction and therapeutic options. J Intern Med 1999; 245: 315-27.
12. Huang PL, Huang Z, Mashimo H, Bloch KD, Moskowitz MA, Bevan JA, et al. Hypertension in mice lacking the gene for endothelial nitric oxide synthase. Nature 1995; 377: 239-42.
13. Napoli C, Ignarro LJ. Nitric oxide and atherosclerosis. Nitric Oxide 2001; 5: 88-97.
14. Rees DD, Palmer RM, Moncada S. Role of endothelium-derived nitric oxide in the regulation of blood pressure. Proc Natl Acad Sci USA 1989; 86: 3375-8.
15. Kelly JJ, Tam SH, Williamson PM, Lawson J, Whitworth JA. The nitric oxide system and cortisol-induced hypertension in humans. Clin Exp Pharmacol Physiol 1998; 25: 945-6.
16. Lou YK, Wen C, Li M, Adams DJ, Wang MX, Yang F, et al. Decreased renal expression of nitric oxide synthase isoforms in adrenocorticotropin-induced and corticosterone-induced hypertension. Hypertension 2001; 37: 1164-70.
17. Mitchell BM, Webb RC. Impaired vasodilation and nitric oxide synthase activity in glucocorticoid-induced hypertension. Biol Res Nurs 2002; 4: 16-21.
18. Qiu C, Baylis C. Dexamethasone worsens nitric oxide inhibition-induced hypertension and renal dysfunction. Am J Hypertens 2000; 13: 1097-1102.
19. Suzuki T, Nakamura Y, Moriya T, Sasano H. Effects of steroid hormones on vascular functions. Microsc Res Tech 2003; 60: 76-84.
20. Wallerath T, Witte K, Schäfer SC, Schwarz PM, Prellwitz W, Wohlfart P, et al. Down-regulation of the expression of endothelial NO synthase is likely to contribute to glucocorticoid-mediated hypertension. Proc Natl Acad Sci USA 1999; 96: 13357-62.
21. Whitworth JA, Schyvens CG, Zhang Y, Andrews MC, Mangos GJ, Kelly JJ. The nitric oxide system in glucocorticoid-induced hypertension. J Hypertens 2002; 20: 1035-43.
22. Mangos GJ. Walker BR, Kelly JJ, Lawson JA, Webb DJ, Whitworth JA. Cortisol inhibits cholinergic vasodilation in the human forearm. Am J Hypertens 2000; 13: 1155-60.
23. Johns DG, Dorrance AM, Tramontini NL, Webb RC. Glucocorticoids inhibit tetrahydrobiopterin-dependent endothelial function. Exp Biol Med (Maywood) 2001; 226: 27-31.
24. Schlegel A, Volonté D, Engelman JA, Galbiati F, Mehta P, Zhang X-L, et al. Crowded little caves: Structure and function of Caveolae. Cell Signal 1998; 10: 457-63.
25. Fleming I, Busse R. Activation of NOS by Ca2+-dependent and Ca2+-independent mechanisms, In: Nitric Oxide Biology and Pathobiology (1st ed.), edited by Ignarro LJ. New York, NY: Academic Press, 2000; p. 621-632.
26. Kone BC. Protein-protein interactions controlling nitric oxide synthases. Acta Physiol Scand 2000; 168: 27-31.
27. Förstermann U, Boissel J-P, Kleinert H. Expressional control of the 'constitutive' isoforms of nitric oxide synthase (NOS I and NOS II). FASEB J 1998; 12: 773-90.
28. Kone BC. Molecular biology of natriuretic peptides and nitric oxide synthases. Cardiovasc Res 2001; 51: 429-41.
29. Adcock IM, Gilbey T, Gelder CM, Chung KF, Barnes PJ. Glucocorticoid receptor localization in normal and asthmatic lung. Am J Respir Crit Care Med 1996; 154: 771-82.
30. Inoue H, Umesono K, Nishimori T, Hirata Y, Tanabe T. Glucocorticoid-mediated suppression of the promoter activity of the cyclooxygenase-2 gene is modulated by expression of its receptor in vascular endothelial cells. Biochem Biophys Res Commun 1999; 254: 292-8.
31. Jun SS, Chen Z, Pace MC, Shaul PW. Glucocorticoids downregulate cyclooxygenase-1 gene expression and prostacyclin synthesis in fetal pulmonary artery endothelium. Circ Res 1999; 84: 193-200.
32. Rogers KM, Bonar CA, Estrella JL, Yang S. Inhibitory effect of glucocorticoid on coronary artery endothelial function. Am J Physiol 2002; 283: H1922-8.
33. Xiao D, Huang X, Bae S, Ducsay CA Zhang L. Cortisol-mediated potentiation of uterine artery contractility: effect of pregnancy. Am J Physiol 2002; 283: H238-46.
34. Best R, Nelson SM, Walker BR. Dexamethasone and 11-dehydrodexamethasone as tools to investigate the isozymes of 11-hydroxysteroid dehydrogenase in vitro and in vivo. J Endocrinol 1997; 153: 41-8.
35. Diederich S, Hanke B, Burkhardt P, Müller M, Schöneshöfer M, Bähr V, et al. Metabolism of synthetic corticosteroids by 11-hydroxysteroid dehydrogenases in man. Steroids 1998; 63: 271-7.
36. Ferrari P, Smith RE, Funder JW, Krozowski ZS. Substrate and inhibitor specificity of the cloned human 11β-hydroxysteroid dehydrogenase type 2 isoform. Am J Physiol 1996; 270: E900-4.
37. Eyre LJ, Rabbitt EH, Hughes SV, Cooper MS, Sheppard MC, Stewart PM, et al. Expression of 11β-hydroxysteroid dehydrogenase in rat osteoblastic cells: pre-receptor regulation of glucocorticoid responses in bone. J Cell Biochem 2001; 81: 453-62.
38. Brem AS, Bina RB, King TC, Morris DJ. Localization of 2 11beta-OH steroid deghydrogenase isoforms in aortic endothelial cells. Hypertension 1998; 31: 459-62.
39. Ullian ME, Islam MM, Robinson CJ, Fitzgibbon WR, Tobin ET, Paul RV. Resistance to mineralocorticoids in Wistar-Furth rats. Am J Physiol 1997; 272: H1454-61.
40. Krozowski Z, Li KXZ, Koyama K, Smith RE, Obeyesekere VR, Stein-Oakley A, et al. The type I and type II 11-hydroxysteroid dehydrogenase enzymes. J Steroid Biochem Mol Biol 1999; 69: 391-401.
41. White PC, Mune T, Agarwal AK. 11β-Hydroxysteroid dehydrogenase and the syndrome of apparent mineralocorticoid excess. Endocr Rev 1997; 18: 135-56.
42. Page N, Warriar N, Govindan MV. 11β-Hydroxysteroid dehydrogenase activity in human lung cells and transcription regulation by glucocorticoids. Am J Physiol 1994; 267: L464-74.
43. Stewart PM. Cortisol as a mineralocorticoid in human disease. J Steroid Biochem Mol Biol 1999; 69: 403-8.
44. Keller-Wood M. Inhibition of stimulated and basal ACTH by cortisol during ovine pregnancy. Am J Physiol 1996; 271: R130-6.
45. Nolten WE, Rueckert PA. Elevated free cortisol index in pregnancy: possible regulatory mechanisms. Am J Obstet Gynecol 1981; 139: 492-8.
46. Orbach P, Wood CE, Keller-Wood M. Nitric oxide reduces pressor responsiveness during ovine hypoadrenocorticism. Clin Exp Pharmacol Physiol 2001; 28: 459-62.
47. Burnstein KL, Bellingham DL, Jewell CM, Powell-Oliver FE, Cidlowski JA. Autoregulation of glucocorticoid receptor gene expression. Steroids 1991; 56: 52-8.
48. Roesch DM, Keller-Wood M. Differential effects of pregnancy on mineralocorticoid and glucocorticoid receptor availability and immunoreactivity in cortisol feedback sites. Neuroendocrinology 1999; 70: 55-62.
49. Chou YC, Luttge WG. Activated type II receptors in brain cannot rebind glucocorticoids: relationship to progesterone's antiglucocorticoid actions. Brain Res 1988; 440: 67-78.
50. Bird IM, Zhang L, Magness RR. Possible mechanisms underlying pregnancy-induced changes in uterine artery endothelial function. Am J Physiol 2003; 284: R245-58.
51. Sladek SM, Magness RR, Conrad KP. Nitric oxide and pregnancy. Am J Physiol 1997; 272: R441-63.
52. Xiao D-L, Liu Y, Pearce WJ, Zhang L. Endothelial nitric oxide release in isolated perfused ovine uterine arteries: effect of pregnancy. Eur J Pharmacol 1999; 367: 223-30.
53. Xiao D-L, Bird IM, Magness RR, Longo LD, Zhang L. Upregulation of eNOS in pregnant ovine uterine arteries by chronic hypoxia. Am J Physiol 2001; 280: H812-20.
54. Garcia-Cardeña G, Fan R, Shah V, Sorrentino R, Cirino G, Papapetropoulos A, et al. Dynamic activation of endothelial nitric oxide synthase by Hsp90. Nature 1998; 392: 821-4.
55. Pratt WB, Toft DO. Steroid receptor interactions with heat shock protein and immunophilin chaperones. Endocr Rev 1997; 18: 306-61.
56. Felley-Bosco E, Bender FC, Courjault-Gautier F, Bron C, Quest AFG. Caveolin-1 down-regulates inducible nitric oxide synthase via the proteasome pathway in human colon carcinoma cells. Proc Natl Acad Sci USA 2006; 97: 14334-9.
57. Walker G, Pfeilschifter J, Kunz D. Mechanisms of suppression of inducible nitric-oxide synthase (iNOS) expression in interferon (IFN)-?-stimulated RAW 264.7 cells by dexamethasone. J Biol Chem 1997; 272: 16679-87.
58. Burnstock G, Williams M. P2 purinergic receptors: Modulation of cell function and therapeutic potential. J Pharmacol Exp Ther 2000; 295: 862-9.
59. Vials AJ, Burnstock G. Differential effects of ATP- and 2-methylthioATP-induced relaxation in guinea pig coronary vasculature. J Cardiovasc Physiol 1994; 23: 757-64.
60. Bodin P, Burnstock G. Purinergic Signalling: ATP release. Neurochem Res 2001; 26: 959-69.
61. Yang S, Cheek DJ, Westfall DP, Buxton ILO. Purinergic axis in cardiac blood vessels agonist-mediated release of ATP from cardiac endothelial cells. Circ Res 1994; 74: 401-7.
62. Harden KT, Nicholas RA, Schachter JB, Lazarowski ER, Boyer JL. Pharmacological selectivities of molecularly defined subtypes of P2Y receptors, In: The P2 Nucleotide Receptors (1st ed.), edited by Turner JT, Weisman GA, and Fedan JS. Totowa, NJ: Humana Press, 1998; p. 109-134.
63. Yang S, Buxton ILO, Probert CB. Talbot JN, Bradley ME. Evidence for a discrete UTP receptor in cardiac endothelial cells. Br J Pharmacol 1996; 117: 1572-8.
64. x release in human coronary artery endothelium. J Cardiovasc Pharmacol 2000; 36: 242-7.
65. 2+ induced by antigen. Biochem Biophys Acta 1990; 1051: 203-6.
66. Passaquin A-C, Lhote P, Rüegg UT. Calcium influx inhibition by steroids and analogs in C2C12 skeletal muscle cells. Br J Pharmacol 1998; 124: 1751-9.
67. Chen G, Suzuki H. Calcium dependency of the endothelium-dependent hyperpolarization in smooth muscle cells of the rabbit carotid artery. J Physiol 1990; 421: 521-34.
68. Fleming I, Busse R. Signal transduction of eNOS activation. Cardiovasc Res 1999; 43: 532-41.
69. Kan H, Ruan Y, Malik KU. Signal transduction medhanism(s) involved in prostacyclin production elicited by acetylcholine in coronary endothelial cells of rabbit heart. J Pharmacol Exp Ther 1997; 282: 113-22.
70. Saito T, Itoh H, Chun T-H, Fukunaga Y. Yamashita J, Doi K, et al Coordinate regulation of endothelin and adrenomedullin secretion by oxidative stress in endothelial cells. Am J Physiol 2001; 281: H1364-71.
71. + responses in rat aortic smooth muscle cells: effect of dexamethasone. Biochem Pharmacol 1999; 58: 177-82.
72. + influx in vascular smooth muscle in vivo. Endocr Res 1995; 21: 203-10.
73. Burg AW, Brown GM. The biosynthesis of folic acid. 8. Purification and properties of the enzyme that catalyzes the production of formate from carbon atom 8 of guanosine triphosphate. J Biol Chem 1968; 243: 2349-58.
74. Schmidt K, Werner ER. Mayer B, Wachter H, Kukovetz WR. Tetrahydrobiopterin-dependent formation of endothelium-derived relaxing factor (nitric oxide) in aortic endothelial cells. Biochem J 1992; 281: 297-300.
75. Xu R, Sowers JR, Skafar DF, Ram JL. Hydrocortisone modulates the effect of estradiol on endothelial nitric oxide synthase expression in human endothelial cells. Life Sci 2001; 69: 2811-7.
76. Corson MA, James NL, Latta SE, Nerem RM, Berk BC, Harrison DG. Phosphorylation of endothelial nitric oxide synthase in response to fluid shear stress. Circ Res 1996; 79: 984-91.
77. Dimmeler S, Fleming I, Fisslthaler B, Hermann C, Busse R, Zeiher AM. Activation of nitric oxide synthase in endothelial cells by Akt-dependent phosphorylation. Nature 1999; 399: 601-5.
78. Fulton D, Gratton JP, McCabe TJ, Fontana J, Fujio Y, Walsh K, et al. Regulation of endothelium-derived nitric oxide production by the protein kinase Akt. Nature 1999; 399: 597-601.
79. Bird IM, Sullivan JA, Di T, Cale JM, Zhang L, Zheng J, et al. Pregnancy-dependent changes in cell signaling underlie changes in differential control of vasodilator production in uterine artery endothelial cells. Endocrinology 2000; 141: 1107-17.
80. Chen Z, Yuhanna IS, Galcheva-Gargova Z, Karas RH, Mendelsohn ME, Shaul PW. Estrogen receptor alpha mediates the nongenomic activation of endothelial nitric oxide synthase by estrogen. J Clin Invest 1999; 103: 401-6.
81. Di T, Sullivan JA, Magness RR, Zhang L, Bird IM. Pregnancy-specific enhancement of agonist-stimulated ERK-1/2 signaling in uterine artery endothelial cells increases Ca(2+) sensitivity of endothelial nitric oxide synthase as well as cytosolic phospholipase A(2). Endocrinology 2001; 142: 3014-26.
82. Ayroldi E, Zollo O, Macchiarulo A, Di Marco B, Marchetti C, Riccardi C. Glucocorticoid-induced leucine zipper inhibits the Raf-extracellular signal-regulated kinase pathway by binding to Raf-1. Mol Cell Biol 2002; 22: 7929-41.
83. Greenberg AK, Hu J, Basu S, Hay J, Reibman J, Yie TA, et al. Glucocorticoids inhibit lung cancer cell growth through both the extracellular signal-related kinase pathway and cell cycle regulators. Am J Respir Cell Mol Biol 2002; 27: 320-8.
84. Kassel O, Sancono A, Kratzschmar J, Kreft B, Stassen M, Cato AC. Glucocorticoids inhibit MAP kinase via increased expression and decreased degradation of MKP-1. EMBO J 2001; 20: 7108-16.
85. Rosenkrantz B, Naray-Fejes-Toth A, Fejes-Toth G, Fischer C, Sawada M, Frolich JC. Dexamethasone effect on prostanoid formation in healthy man. Clin Sci (Lond) 1985; 68: 681-5.
86. Sebaldt RJ, Sheller JR, Oates JA, Roberts LJ 2nd, FitzGerald GA. Inhibition of eicosanoid biosynthesis by glucocorticoids in humans. Proc Natl Acad Sci USA 1990; 87: 6974-8.
87. Falardeau P, Martineau A. Prostaglandin 12 and glucocorticoid-induced rise in arterial pressure in the rat. J Hypertens 1989; 7: 625-32.
88. Grunfeld JP, Eloy L, Araujo A, Russo-Marie F. Effects of gluco- and antiglucocorticoids on renal and aortic prostaglandin synthesis. Am J Physiol 1986; 251: F810-6.
89. Ibe BO, Okogbule-Wonodi AC, Raj JU. Antenatal glucocorticoid treatment attenuates immediate postnatal prostacyclin and thromboxane levels in plasma of very preterm lambs. Biol Neonate 1996; 69: 153-64.
90. Crutchley DJ, Ryan US, Ryan JW. Glucocorticoid modulation of prostacyclin production in cultured bovine pulmonary endothelial cells. J Pharmacol Exp Ther 1985; 233: 650-5.
91. Hullin F, Raynal P, Ragab-Thomas JM, Fauvel J, Chap H. Effect of dexamethasone on prostaglandin synthesis and on lipocortin status in human endothelial cells. Inhibition of prostaglandin 12 synthesis occurring without alteration of arachidonic acid liberation and of lipocortin synthesis. J Biol Chem 1989; 264: 3506-13.
92. Jeremy JY, Dandona P. Inhibition by hydrocortisone of prostacyclin synthesis by rat aorta and its reversal with RU486. Endocrinology 1986; 119: 661-5.
93. Lewis GD, Campbell WB, Johnson AR. Inhibition of prostaglandin synthesis by glucocorticoids in human endothelial cells. Endocrinology 1986; 119: 62-9.
94. Rosenstock M, Katz S, Danou A. Glucocorticoids regulate both phorbol ester and calcium ionophore-induced endothelial prostacyclin synthesis. Prostaglandins Leukot Essent Fatty Acids 1997; 56: 1-8.
95. Vane JR, Bakhle YS, Botting RM. Cyclooxygenases 1 and 2. Annu Rev Pharmacol Toxicol 1998; 38: 97-120.
96. Besse JC, Bass AD. Potentiation by hydrocortisone of responses to catecholamines in vascular smooth muscle. J Pharmacol Exp Ther 1966; 154: 224-38.
97. Kadowitz PJ, Yard AC. Influence of hydrocortisone on cardiovascular responses to epinephrine. Eur J Pharmacol 1971; 13: 281-6.
98. Kalsner S. Mechanism of hydrocortisone potentiation of responses to epinephrine and norepinephrine in rabbit aorta. Circ Res 1969; 24: 383-95.
99. Yard AC, Kadowitz PJ. Studies on the mechanism of hydrocortisone potentiation of vasoconstrictor responses to epinephrine in the anesthetized animal. Eur J Pharmacol 1972; 20: 1-9.
100. Fritz I, Levine R. Action of adrenal cortical steroids and norepinephrine on vascular responses of stress in adrenalectomized rats. Am J Physiol 1951; 165: 456-65.
101. Swingle WW, Swingle AJ. Development of chronic low plasma volumes in long-term adrenalectomized dogs. Proc Soc Exp Biol Med 1967; 125: 811-3.
102. Loriaux DL. Adrenocortical insufficiency. In: Becker KL (ed). Principles and Practice of Endocrinology and Metabolism. JB Lippincott, Philadelphia, 1990; 600-604.
103. Berecek KH, Bohr DF. Whole body vascular reactivity during the development of deoxycorticosterone acetate hypertension in the pig. Circ Res 1978; 42: 764-71.
104. Handa M, Kondo K, Suzuki H, Satura T. Dexamethasone hypertension in rats: role of prostaglandins and pressor sensitivity to norepinephrine. Hypertension 1984; 6: 236-41.
105. Kurland GS, Freedberg AS. The potentiating effect of ACTH and of cortisone on pressor response to intravenous infusion of 1-norepinephrine. Proc Soc Exp Med Biol 1951; 78: 28-31.
106. Pirpiris M, Sudhir K, Yeung S, Jennings G, Whitworth JA. Pressor responsiveness in corticosteroid-induced hypertension in humans. Hypertension 1992; 19: 567-74.
107. Whitworth JA, Connell JM, Lever AF, Fraser R. Pressor responsiveness in steroid-induced hypertension in man. Clin Exp Pharmacol Physiol 1986; 13: 353-8.
108. Gaillard RC, Poffet D, Riondel AM, Saurat JH. RU486 inhibits peripheral effects of glucocorticoids in humans. J Clin Endocrinol Metab 1985; 61: 1009-11.
109. Marks R, Barlow JW, Funder JW. Steroid-induced vasoconstriction: glucocorticoid antagonist studies. J Clin Endocrinol Metab 1982; 54: 1075-7.
110. Xiao D, Huang X, Pearce WJ, Longo LD, Zhang L. Effect of Cortisol on Norepinephrine-Mediated Contractions in Ovine Uterine Arteries. Am J Physiol 2003; 284: H1142-51.
111. Ullian ME, Walsh LG, Morinelli TA. Potentiation of angiotensin II action by corticosteroids in vascular tissue. Cardiovasc Res 1996; 32: 266-73.
112. Dodie M, Wintour EM. Effects of prolonged (48 h) infusion of cortisol on blood pressure, renal function and fetal fluids in the immature ovine foetus. Clin Exp Pharmacol Physiol 1994; 21: 971-80.
113. Takeishi M, Shibata S, Tsumagari S. Adrenocorticotropin and cortisol levels in the plasma of bovine fetuses and neonates. Nippon Juigaku Zasshi 1989; 51: 975-80.
114. Wood CE, Cheung CY, Brace RA. Fetal heart rate, arterial pressure, and blood volume responses to cortisol infusion. Am J Physiol 1987; 253: R904-9.
115. Anwar MA, Schwab M, Poston L, Nathanielsz PW. Betamethasone-mediated vascular dysfunction and changes in hematological profile in the ovine fetus. Am J Physiol 1999; 276: H1137-43.
116. Hayashi T, Kornel L. Cortisol-21-sulfate (FS) is a specific ligand for intracellular transcortin: demonstration of three types of high affinity corticosteroid binders in bovine aortic cytosol by a combined use of FS and RU 28362. Endocrinology 1990; 126: 307-16.
117. Kornel L, Kanamarlapudi N, Ramsay C, Taff DJ. Studies on arterial mineralocorticoid and glucocorticoid receptors: evidence for the translocation of steroid-cytoplasmic receptor complexes to cell nuclei. Clin Physiol Biochem 1984; 2: 14-31.
118. Kornel L, Kanamarlapudi N, Travers T, Taff DJ, Patel N, Chen C, et al. Studies on high affinity binding of mineralo- and glucocorticoids in rabbit aorta cytosol. J Steroid Biochem 1982; 16: 245-64.
119. Scott BA, Lawrence B, Nguyen HH, Meyer WJ 3rd. Aldosterone and dexamethasone binding in human arterial smooth muscle cells. J Hypertens 1987; 5: 739-44.
120. Kornel L, Nelson WA, Manisundaram B, Chigurupati R, Hayashi T. Mechanism of the effects of glucocorticoids and mineralocorticoids on vascular smooth muscle contractility. Steroids 1993; 58: 580-7.
121. Kato H, Hayashi T, Koshino Y, Kutsumi Y, Nakai T, Miyabo S. Glucocorticoids increase Ca2+ influx through dihydropyridine-sensitive channels linked to activation of protein kinase C in vascular smooth muscle cells. Biochem Biophys Res Commun 1992; 188: 934-41.
122. Kato H, Hayashi T, Koshino Y, Oida K, Kutsumi Y, Nakai T, et al. Autocrine production of endothelin-1 participates in the glucocorticoid-induced Ca2+ influx into vascular smooth muscle cells. Biochem Biophys Res Commun 1995; 208: 82-8.
123. Kanse SM, Takahashi K, Warren JB, Ghatei M, Bloom SR. Glucocorticoids induce endothelin release from vascular smooth muscle cells but not endothelial cells. Eur J Pharmacol 1991; 199: 99-101.
124. Ito Y, Kozawa O, Tokuda H, Suzuki A, Watanabe Y, Kotoyori J, et al. Glucocorticoid inhibits cAMP production induced by vasoactive agents in aortic smooth muscle cells. Atherosclerosis 1994; 110: 69-76.
125. Nuglozeh E, Mbikay M, Stewart DJ, Legault L. Rat natriuretic peptide receptor genes are regulated by glucocorticoids in vitro. Life Sci 1997; 61: 2143-55.
126. Berridge MJ. Inositol triphosphate and calcium signaling. Nature 1993; 361: 315-25.
127. Chadwick CC, Saito A, Fleischer S. Isolation and characterization of the inositol triphosphate receptor from smooth muscle. Proc Natl Acad Sci USA 1990; 87: 2132-6.
128. 2+ channel in planar bilayer. Cell Calcium 1995; 12: 505-14.
129. Somlyo AP, Somlyo AV. Signal transduction and regulation in smooth muscle. Nature 1994; 372: 231-6.
130. Sato A, Suzuki H, Murakami M, Nakazato Y, Iwaita Y, Saruta T. Glucocorticoid increases angiotensin II type I receptor and its gene expression. Hypertension 1994; 23: 25-30.
131. Hegarty BD, Burrell JH, Gibson KJ, McMullen JR, Lumbers ER. Effect of cortisol on fetal ovine vascular angiotensin II receptors and contractility. Eur J Pharmacol 2000; 406: 439-48.
132. Haigh RM, Jones CT, Milligan G. Glucocorticoids regulate the amount of G proteins in rat aorta. J Mol Endocrinol 1990; 5: 185-8.
133. 1B adrenergic receptor gene in DTT1 MF-2 smooth muscle cells. J Clin Invest 1991; 88: 385-9.
134. Haigh RM, Jones CT. Effect of glucocorticoids on alpha 1-adrenergic receptor binding in rat vascular smooth muscle. J Mol Endocrinol 1990; 5: 41-8.
135. Liu J, Haigh RM, Jones CT. Enhancement of noradrenaline-induced inositol polyphosphate formation by glucocorticoids in rat vascular smooth muscle cells. J Endocrinol 1992; 133: 405-11.
136. Sato A, Suzuki H, Iwaita Y, Nakazato Y, Kato H, Saruta T. Dexamethasone potentiates production of inositol triphosphate evoked by endothelin-1 in vascular smooth muscle cells. J Cardiovas Pharmacol 1992; 20: 290-5.
137. Watanabe Y, Tokuda H, Suzuki A, Shinoda J, Kotoyori J, Ito Y, et al. Glucocorticoid amplifies vasopressin-induced phospho-inositide hydrolysis in aortic smooth muscle cells. J Cell Biochem 1995: 57: 522-9.
138. Saito N, Guitart X, Hayward M, Tallman JF, Duman RS, Nestler EJ. Corticosterone differentially regulates the expression of Gs alpha and Gi alpha messenger RNA and protein in rat cerebral cortex. Proc Natl Acad Sci USA 1989; 86: 3906-10.
139. Dwivedi Y, Pandey GN. Repeated administration of dexamethasone increases phosphoinositide-specific phospholipase C activity and mRNA and protein expression of the phospholipase C beta 1 isozyme in rat brain. J Neurochem 1999; 73: 780-90.
140. Hu X-Q, Yang SM, Pearce WJ, Longo LD, Zhang L. Effect of chronic hypoxia on Alpha-1 adrenoceptor-mediated Inositol 1,4,5-Triphosphate signaling in ovine uterine artery. J Pharmacol Exp Ther 1999; 288: 977-83.
141. Zhou L, Zhao Y, Nijland R, Zhang L, Longo LD. Inositol 1,4,5-triphosphate receptors in cerebral arteries: Changes with development and long-term hypoxia. Am J Physiol 1997; 272: R1954-9.
142. 2+-release. FEBS Lett 1991; 291: 113-6.
143. Dwivedi Y, Rizavi HS, Rao JS, Pandey GN. Modifications in the phosphoinositide signaling pathway by adrenal glucocorticoids in rat brain: focus on phosphoinositide-specific phospholipase C and inositol 1,4,5-triphosphate. J Pharmacol Exp Ther 2000; 295: 244-54.
144. Bradley AB, Morgan KG. Alterations in cytoplasmic calcium sensitivity during porcine coronary artery contractions as detected by aequorin. J Physiol 1987; 385: 437-48.
145. 2+] determines myosin phosphorylation in agonist-stimulated swine arterial smooth muscle. Circ Res 1988; 63: 593-603.
146. 2+ sensitivity of myofilaments in uterine arteries. Am J Physiol 1998; 274: H132-8.
147. 2+ homeostasis in human myometrial smooth muscle cells. Am J Physiol 1999; 276: C379-85.
148. Niiro N, Nishimura J, Sakihara C, Nakano H, Kanaide H. Up-regulation of rho A and rho-kinase mRNAs in the rat myometrium during pregnancy. Biochem Biophys Res Commun 1997; 230: 356-9.
149. Trujillo M, Candenas L, Cintado CG, Magraner J, Fernandez J, Martin JD, et al. Hormonal regulation of the contractile response induced by okadaic acid in the rat uterus. J Pharmacol Exp Ther 2001; 296: 841-8.
150. Loirand G, Cario-Toumaniantz C, Chardin P, Pacaud P. The Rho-related protein Rnd1 inhibits Ca2+ sensitization of rat smooth muscle. J Physiol 1999; 516: 825-34.
151. Hatakeyama H, Inaba S, Taniguchi N, Miyamori I. Functional adrenocorticotropic hormone receptor in cultured human vascular endothelial cells : possible role in control of blood pressure. Hypertension 2000; 36: 862-5.
152. Walker BR. Organ-specific actions of 11 beta-hydroxysteroid dehydrogenase in humans: implications for the pathophysiology of hypertension. Steroids 1994; 59: 84-9.
153. Brem AS, Bina RB, King TC, Morris DJ. Bidirectional activity of 11 beta-hydroxysteroid dehydrogenase in vascular smooth muscle cells. Steroids 1995; 60: 406-10.
154. Takeda Y, Miyamori I, Yoneda T, Ito Y, Takeda R. Expression of 11 beta-hydroxysteroid dehydrogenase mRNA in rat vascular smooth muscle cells. Life Sci 1994; 54: 281-5.
155. Hatakeyama H, Inaba S, Miyamori I. 11beta-hydroxysteroid dehydrogenase in cultured human vascular cells. Possible role in the development of hypertension. Hypertension 1999; 33: 1179-84.
156. Hatakeyama H, Inaba S, Miyamori I. 11beta-hydroxysteroid dehydrogenase activity in human aortic smooth muscle cells. Hypertens Res 2001; 24: 33-7.
157. Smith RE, Little PJ, Maguire JA, Stein-Oakley AN, Krozowski ZS. Vascular localization of the 11 beta-hydroxysteroid dehydrogenase type II enzyme. Clin Exp Pharmacol Physiol 1996; 23: 549-51.
158. Kornel L. Colocalization of 11 beta-hydroxysteroid dehydrogenase and mineralocorticoid receptors in cultured vascular smooth muscle cells. Am J Hypertens 1994; 7: 100-3.
159. Teelucksingh S, Mackie AD, Burt D, McIntyre MA, Brett L, Edwards CR. Potentiation of hydrocortisone activity in skin by glycyrrhetinic acid. Lancet 1990; 335: 1060-3.
160. Walker BR, Best R. Clinical investigation of 11 beta-hydroxysteroid dehydrogenase. Endocr Res 1995; 21: 379-87.
161. Walker BR, Connacher AA, Webb DJ, Edwards CR. Glucocorticoids and blood pressure: a role for the cortisol/cortisone shuttle in the control of vascular tone in man. Clin Sci (Lond) 1992; 83: 171-8.
162. Walker BR, Best R, Shackleton CH, Padfield PL, Edwards CR. Increased vasoconstrictor sensitivity to glucocorticoids in essential hypertension, Hypertension 1996; 27: 190-6.
163. Takeda Y, Yoneda T, Miyamori I, Gathiram P, Takeda R. 11 beta-Hydroxysteroid dehydrogenase activity in mesenteric arteries of spontaneously hypertensive rats. Clin Exp Pharmacol Physiol 1993; 20: 627-31.
164. Takeda Y, Miyamori I, Yoneda T, Halakeyama H, Iki K, Takeda R. Decreased activity of 11 beta-hydroxysteroid dehydrogenase in mesenteric arteries of Dahl salt-sensitive rats. Life Sci 1994; 54: 1343-9.
165. Souness GW, Brem AS, Morris DJ. 11 beta-Hydroxysteroid dehydrogenase antisense affects vascular contractile response and glucocorticoid metabolism. Steroids 2002; 67: 195-201.
166. van Uum SH, Walker BR, Hermus AR, Sweep CG, Smits P, de Leeuw PW, et al. Effect of glycyrrhetinic acid on 11 beta-bydroxysteroid dehydrogenase activity in normotensive and hypertensive subjects. Clin Sci (Lond) 2002; 102: 203-11.
167. Kotelevtsev Y, Brown RW, Fleming S, Kenyon C, Edwards CR, Seckl JR, et al. Hypertension in mice lacking 11beta-hydroxysteroid dehydrogenase type 2. J Clin Invest 1999; 103: 683-9.
168. Hadoke PW, Christy C, Kotelevtsev YV, Williams BC, Kenyon CJ, Seckl JR, et al. Endothelial cell dysfunction in mice after transgenic knockout of type 2, but not type 1, 11beta-hydroxysteroid dehydrogenase. Circulation 2001; 104: 2832-7.
169. Ruschitzka F, Quaschning T, Noll G, deGottardi A, Rossier MF, Enseleit F, et al. Endothelin 1 type a receptor antagonism prevents vascular dysfunction and hypertension induced by 11beta-hydroxysteroid dehydrogenase inhibition: role of nitric oxide. Circulation 2001; 103: 3129-35.